Three Rivers Announces Positive Results from Phase 3 DIRECT Trial of Once-Daily INFERGEN(R)...

Three Rivers Announces Positive Results from Phase 3 DIRECT Trial of
Once-Daily INFERGEN(R) with Ribavirin in Hepatitis C Virus Treatment Failures

WARRENDALE, Pa., June 16 /PRNewswire/ -- Three Rivers Pharmaceuticals
announced today positive results of the U.S.-based, randomized Daily-Dose
Consensus Interferon and Ribavirin: Efficacy of Combined Therapy (DIRECT)
clinical trial authored by Bruce R. Bacon, M.D., of Saint Louis University,
and colleagues at 44 centers in the United States. The primary endpoint of
increased sustained virological response (SVR), was achieved demonstrating
that INFERGEN provides a second chance to those HCV patients failing to
respond to standard, first-line therapy of pegylated interferon (PEG-IFN) plus
ribavirin (RBV). "The retreatment of PEG-IFN/RBV nonresponders with INFERGEN
and RBV is safe and efficacious and can be considered a retreatment strategy
for patients failing previous therapy with PEG-IFN/RBV, especially in
interferon-sensitive patients with lower baseline fibrosis scores," stated Dr.
Bruce Bacon the lead Investigator for the study.

Among participants who failed initial treatment with PEG-IFN/RBV, retreatment
with INFERGEN in combination with RBV yielded SVR rates as high as 31.6 % in
interferon-sensitive patients with low baseline liver fibrosis scores, the
researchers reported in the June 2009 issue of Hepatology. Overall intent to
treat analysis was 6.9% among the 9 mcg/day group and 10.7% in the 15 mcg/day
group.

Defining viral response at Weeks 12 and 24 with INFERGEN and RBV in patients
who were prior non-responders to PEG-IFN/RBV therapy can help predict SVR
rates in this difficult-to-treat group of patients. All patients attaining SVR
demonstrated > 2-log drop at Week 12 of INFERGEN/RBV therapy. Of significant
note for these patients was the analysis regarding viral response at 12 weeks.
In the DIRECT trial, 81.3% and 63.6% of patients achieving viral negativity
at Week 12 went on to have an SVR in the 9 mcg and 15 mcg arms, respectively.
In addition, slow responders achieved SVR rates of 11.7% and 35.4% in the 9
mcg and 15 mcg arms. Regardless of treatment dose used, attaining viral
negativity at Week 12 or at Week 24 while on therapy with INFERGEN and RBV
leads to a high sustained virological response rate.

"These results represent a significant step forward for HCV patients who
deserve a second chance at a potential cure for this chronic viral infection"
stated Donald Kerrish, President and CEO of Three Rivers Pharmaceuticals.

Approximately 50% of patients with chronic hepatitis C fail to respond to
their initial course of PEG-IFN/RBV therapy. No standard has yet emerged for
second-line therapy, since simply repeating the same treatment, in well
controlled trials, has yielded low response rates around 2-6%.

The DIRECT trial was a phase 3, randomized, open-label, multicenter,
U.S.-based trial conducted to investigate the efficacy, tolerability, and
safety of daily INFERGEN at dosages of 9 and 15 mcg/day administered with
daily weight-based RBV. The study tested 2 dosages of INFERGEN in 487
documented non-responders, of which 80% did not achieve a 2-log drop on prior
pegylated-interferon plus ribavirin therapy. The best SVR rates were seen in:

-- Patients achieving the greatest reduction in baseline viral load with
peg-IFN/RBV therapy, especially in patients demonstrating > 1-log
drop with initial therapy
-- Patients with fibrosis scores of F0 to F3 at baseline demonstrated
SVRs
of 7.8% in the 9 mcg arm and 13.1% in the 15 mcg arm
-- Patients maintaining full dose of INFERGEN/RBV therapy had SVRs of 7%
and 17% for the 9 mcg and 15 mcg arms respectively
-- Patients demonstrating partial response (>2-log drop) with previous
treatment and low fibrosis scores F0-F3 had SVRs of 10.7% and 31.6%
for
the 9 mcg and 15 mcg arms

Patients with cirrhosis were less likely to benefit from retreatment with
INFERGEN and RBV unless they displayed previous interferon sensitivity of at
least 1-log drop in viral levels on prior therapy.

About Consensus Interferon (INFERGEN(R))
Consensus Interferon or INFERGEN(R) is a unique, bio-optimized, selective and
highly potent type 1 interferon alpha. INFERGEN is indicated for the
treatment of chronic HCV infection in patients 18 years of age or older with
compensated liver disease who have anti-HCV serum antibodies and /or the
presence of HCV RNA. INFERGEN is currently FDA approved for TIW monotherapy
dosing in naive and previous treatment failure patients.

Important Safety Information
Physicians and patients can obtain additional prescribing information
regarding INFERGEN, including the product's safety profile and the box warning
for all interferon alphas regarding neuropsychiatric, autoimmune, ischemic and
infectious disorders, by visiting www.infergen.com.

About Hepatitis C
Hepatitis means inflammation of the liver. Hepatitis C is a liver disease that
results from infection with the hepatitis C virus. It can range in severity
from a mild illness lasting a few weeks to a serious, lifelong illness.
Hepatitis C can be either "acute" or "chronic." Acute hepatitis C virus
infection is a short-term illness that occurs within the first 6 months after
someone is exposed to the hepatitis C virus. For most people, acute infection
leads to chronic infection. Chronic hepatitis C is a serious disease than can
result in long-term health problems, or even death. There is no vaccine for
hepatitis C.

About Three Rivers Pharmaceuticals
Three Rivers Pharmaceuticals is a privately held company headquartered in
Warrendale, Pennsylvania that focuses on specialized therapies including
hepatitis C therapies. More information about the company can be found at
www.3riverspharma.com.

SOURCE Three Rivers Pharmaceuticals, LLC

Paul Fagan of Three Rivers Pharmaceuticals, +1-724-778-6007,
pfagan@3riverspharma.com